Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of orelabrutinib + rituximab + high-dose methotrexate followed by autologous HSCT in newly diagnosed PCNSL
ChiCTR2200061485Phase 2Not yet recruiting
- Sponsor
- Department of Hematology, Qilu Hospital, Shandong University
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of orelabrutinib, rituximab and methotrexate in primary central nervous system lymphoma (PCNSL), sponsored by Department of Hematology, Qilu Hospital, Shandong University. Primary endpoints: Overall response rate and Complete response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
orelabrutinibrituximabmethotrexate
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2200061485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061485.